Viridian Therapeutics (0K1R) Share Forecast & Price Target
0K1R Analyst Ratings
Strong Buy
12Buy0Hold0Sell
Based on 12 analysts giving stock ratings to Viridian Therapeutics in the past 3 months
0K1R Stock 12 Month Forecast
Average Price Target
$34.11▲(40.06% Upside)Based on 12 Wall Street analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $34.11 with a high forecast of $41.00 and a low forecast of $22.00. The average price target represents a 40.06% change from the last price of $24.36.
Past 12 Months12 Month ForecastDec2025Sep2026
High$41.00
Average$34.11
Low$22.00
Highest Price TargetHighest$41.00Average Price Target$34.11Lowest Price TargetLowest$22.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Gavin Clark-Gartner | Evercore ISI | $26 | buy | 6.75%Upside | Reiterated | 10/30/26 | ||
| Derek Archila | Wells Fargo | $31 | buy | 27.28%Upside | Assigned | 10/14/26 | ||
| Lisa Walter | RBC Capital | $38 | buy | 56.03%Upside | Reiterated | 10/08/26 | ||
| Rami Katkhuda | LifeSci Capital | $35 | buy | 43.71%Upside | Reiterated | 10/02/26 | ||
| Gregory Renza | Truist Financial | ― | buy | ― | Reiterated | 09/01/26 | ||
| Richard Law CFA | Goldman Sachs | $39→$40 | buy | 64.24%Upside | Reiterated | 08/19/26 | ||
| Alex Thompson CFA | Stifel Nicolaus | $40 | buy | 64.24%Upside | Reiterated | 08/13/26 | ||
| Douglas Tsao | H.C. Wainwright | $22 | buy | -9.67%Downside | Reiterated | 08/07/26 | ||
| Laura Chico | Wedbush | $43→$41 | buy | 68.34%Upside | Reiterated | 08/06/26 | ||
| Serge Belanger | Needham | $34 | buy | 39.60%Upside | Reiterated | 08/06/26 | ||
| Lachlan Hanbury Brown | William Blair | ― | buy | ― | Reiterated | 08/06/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Reiterated | 08/06/26 | ||
| Faisal Khurshid | Jefferies | $30 | buy | 23.18%Upside | Reiterated | 06/30/26 | ||
| Thomas Smith | Leerink Partners | $50 | buy | 105.30%Upside | Reiterated | 04/06/26 | ||
| Michael Yee | UBS | $50 | buy | 105.30%Upside | Initiated | 01/07/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Gavin Clark-Gartner | 10/30/26 | $26 | buy | 6.75%Upside | Reiterated | Evercore ISI | ||
| Derek Archila | 10/14/26 | $31 | buy | 27.28%Upside | Assigned | Wells Fargo | ||
| Lisa Walter | 10/08/26 | $38 | buy | 56.03%Upside | Reiterated | RBC Capital | ||
| Rami Katkhuda | 10/02/26 | $35 | buy | 43.71%Upside | Reiterated | LifeSci Capital | ||
| Gregory Renza | 09/01/26 | ― | buy | ― | Reiterated | Truist Financial | ||
| Richard Law CFA | 08/19/26 | $39→$40 | buy | 64.24%Upside | Reiterated | Goldman Sachs | ||
| Alex Thompson CFA | 08/13/26 | $40 | buy | 64.24%Upside | Reiterated | Stifel Nicolaus | ||
| Douglas Tsao | 08/07/26 | $22 | buy | -9.67%Downside | Reiterated | H.C. Wainwright | ||
| Laura Chico | 08/06/26 | $43→$41 | buy | 68.34%Upside | Reiterated | Wedbush | ||
| Serge Belanger | 08/06/26 | $34 | buy | 39.60%Upside | Reiterated | Needham | ||
| Lachlan Hanbury Brown | 08/06/26 | ― | buy | ― | Reiterated | William Blair | ||
| Joseph Thome | 08/06/26 | ― | buy | ― | Reiterated | TD Cowen | ||
| Faisal Khurshid | 06/30/26 | $30 | buy | 23.18%Upside | Reiterated | Jefferies | ||
| Thomas Smith | 04/06/26 | $50 | buy | 105.30%Upside | Reiterated | Leerink Partners | ||
| Michael Yee | 01/07/26 | $50 | buy | 105.30%Upside | Initiated | UBS |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Viridian Therapeutics
3 Months
Success Rate15/22 ratings generated profit
68%
Average Return
+13.40%
Copying Douglas Tsao's trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +13.40% per trade.
1 Year
Success Rate17/22 ratings generated profit
77%
Average Return
+22.79%
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 77.27% of your transactions generating a profit, with an average return of +22.79% per trade.
2 Years
Success Rate21/22 ratings generated profit
95%
Average Return
+37.72%
Copying Douglas Tsao's trades and holding each position for 2 Years would result in 95.45% of your transactions generating a profit, with an average return of +37.72% per trade.
0K1R Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 34 | 21 | 20 | 11 | 12 |
| Buy | 8 | 5 | 6 | 5 | 6 |
| Hold | 2 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 44 | 27 | 27 | 16 | 18 |
In the current month, 0K1R has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0K1R average Analyst price target in the past 3 months is 34.11.
0K1R Financial Forecast
High$-0.78
Consensus$-1.02
Low$-1.26
0K1R Earnings Forecast
Next quarter’s earnings estimate for 0K1R is -$1.02 with a range of -$1.26 to -$0.78. The previous quarter’s EPS was -$1.05. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$15M
Consensus$4.72M
Low$0.00
0K1R Sales Forecast
Next quarter’s sales forecast for 0K1R is $4.72M with a range of $0 to $15.00M. The previous quarter’s sales results were $284.00K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0K1R Stock Forecast FAQ
What is GB:0K1R’s average 12-month price target, according to analysts?
Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is $34.11.
What is GB:0K1R’s upside potential, based on the analysts’ average price target?
Viridian Therapeutics has 40.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Viridian Therapeutics a Buy, Sell or Hold?
Viridian Therapeutics has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Viridian Therapeutics’s share price target?
The average share price target for Viridian Therapeutics is $34.11. This is based on 12 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $41.00, and the lowest forecast is $22.00. The average share price target represents a 40.06% increase from the current price of $24.355.
What do analysts say about Viridian Therapeutics?
Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of Viridian Therapeutics?
To buy shares of GB:0K1R, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.